CAR T cell therapy is designed to use the immune system to find and eliminate cancer cells. This therapy is often used to treat types of aggressive blood cancers like lymphoma and leukemia. Prior studies have found that cancer cells have learned how to evade the immune system to avoid elimination.

Scinai Immunotherapeutics (NASDAQSCNI) has established a U.S.-based subsidiary, Scinai Bioservices Inc., to enhance its Contract Development and Manufacturing Organization (CDMO) operations and address the growing demand for early-stage biologics development in the U.S. Operating from a cGMP-compliant facility in Jerusalem, Israel, Scinai Bioservices has supported nine biotech companies since its 2024 launch and recently signed its first U.S. customer, Serpin Pharma. The new subsidiary will provide boutique CDMO services tailored to early-stage biotech startups, leveraging U.S. grant funding opportunities while addressing concerns related to the BIOSECURE Act. Scinai anticipates significant growth in its CDMO revenues and reputation in the coming years.

Parvovirus B19, often referred to as the B19 virus, is a seasonal respiratory viral illness that is transmitted through respiratory secretions from an infected individual’s sneezes or coughs, their blood or blood products, or through vertical transmission from a pregnant woman to her baby.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. Michael Schön is a distinguished professor and director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He also serves as vice dean and deputy director for research and teaching and is the former director of the Lower Saxony Institute of Occupational Dermatology.

Scinai Immunotherapeutics (NASDAQSCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, where he will support the advancement of the company’s IL-17 program and VHH antibody pipeline. Dr. Sadeh brings over 20 years of drug development experience, including senior leadership roles at Bristol-Myers Squibb, where he led programs in immunology, cardiovascular, and neuroscience, and was instrumental in the approval of Sotyktu for psoriasis. With a background in pulmonary and critical care from Harvard Medical School and a focus on innovative therapies addressing unmet medical needs, Dr. Sadeh expressed enthusiasm for Scinai’s bio-better approach and collaborations with institutions like Max Planck and UMG. CEO Amir Reichman emphasized Dr. Sadeh’s invaluable expertise in advancing Scinai’s mission to deliver transformative therapies.

New research by scientists from the Oregon Health & Science University and Johns Hopkins Kimmel Cancer Center has found a new approach that can make tumors resistant to immunotherapy vulnerable to the treatment.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing innovative biological products targeting inflammation and immunology (“I&I”) and offering contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices division, released its financial results for the nine months ending Sept. 30, 2024. The announcement highlights the company’s progress in advancing its I&I-focused pipeline and the expansion of its CDMO operations, showcasing its commitment to delivering high-quality biologics and fostering strategic partnerships. This update reflects Scinai’s efforts to strengthen its position in the biopharmaceutical and CDMO markets, aligning with its broader vision of growth and innovation.

Thus far, Rwanda has confirmed the presence of 64 cases of Marburg virus disease, a type of viral hemorrhagic fever. This virus is transmitted to humans from fruit bats and spreads from one individual to another through human-to-human transmission.

Scinai Immunotherapeutics (NASDAQSCNI) will showcase its inflammation and immunology (“I&I”) product pipeline and contract development and manufacturing (“CDMO”) services at the BIO-Europe 2024 conference in Stockholm from November 4-6. CEO Amir Reichman and CTO Dr. Dalit Weinstein-Fischer will meet with potential clients, pharma partners and investors to discuss co-development opportunities in I&I, collaborations in dermatology, particularly for their Botox-like psoriasis treatment and Scinai’s CDMO capabilities. Scinai will also exhibit at booth #150, where interested parties can learn more about their end-to-end biologics services.

The 20th century saw many advancements being adopted in the medical field, among them, potable water, penicillin and, most importantly, vaccines. Vaccines have saved millions of lives, from the eradication of smallpox globally in the 1980s to their use in curbing the spread of the coronavirus in 2020.

New figures released by the CDC show that whooping cough cases have increased significantly in the United States since 2023. The rise in cases has been attributed to a reduction in rates of vaccination, which started during the pandemic.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced plans to host a scientific webinar to discuss the plaque psoriasis landscape, current treatment methods, and existing unmet needs in treating mild to moderate plaque psoriasis. The virtual panel discussion will also explore intralesional injections of the company’s novel anti-IL-17A/F VHH single domain VHH antibodies as a promising solution. Other topics will include an introduction to single domain VHH antibodies and the company’s pipeline, with panelists also reviewing the biological drug development journey toward marketing authorization. The webinar is scheduled for Wednesday, September 18, 2024, at 11 a.m. EDT/ 6 p.m. Israel time.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s business model as well as entities and experts the company works closely with. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation.

Colorectal cancer presents in many forms, with the most common type being microsatellite-stable colorectal cancer. This cancer type is common in the initial stages of colon cancer and rectal cancer, occurring in roughly 85% of colorectal cancers.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has closed on its previously announced loan restructuring agreement. According to the announcement, the agreement is with the European Investment Bank (“EIB”) and includes an amendment.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms of the agreement, Scinai may issue and sell ASDs to the investor, from time to time through December 31, 2024, for an aggregate purchase price of up to $2 million. The agreement does not require the company to register for resale the ADSs to be issued under the agreement.

Scinai Immunotherapeutics just reported results for the second quarter of 2024.

Scinai Immunotherapeutics (NASDAQSCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss its Q2 2024 results and business update on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time.

Scinai Immunotherapeutics (NASDAQSCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance Contract between the parties.

Australia recently launched a countrywide immunotherapy program for infants with peanut allergies. The program is a partnership between the Murdoch Children’s Research Institute and the country’s National Allergy Center of Excellence. This is the first time a countrywide program for peanut allergies is being integrated into mainstream care globally.

There's nothing wrong with taking a chance on an up-and-coming company, but these F-rated stocks to sell aren't worth your time.

New research has highlighted the increased risk of illnesses spreading to humans from animals. The report by researchers from New York University and Harvard Law School examined common interactions between humans and animals in 15 countries, including the United States.